Quality Medicines to combat Antibiotic Resistance: At the turn of the century, the World Health Organization estimated that infections accounted for 45% of deaths in Africa. Also think of this gloomy statistic — by 2050 antimicrobial resistance (AMR) could lead to deaths of 4.15 million people in Africa every year¹. The only continent that will overtake Africa is Asia, which could see 4.73 million people die from this canker over the same period. The use of antimicrobial agents plays a critical role in reducing the morbidity and mortality due to communicable diseases, a major disease burden for the African region. However, the emergence and spread of resistance to many of the available agents are negating their effectiveness. Drug resistance has dramatically increased the costs of fighting major diseases on the continent including, ranging from increased hospital visits, repetitive medicine costs and loss of man-hours. While appearance of drug resistance is a continuous phenomenon in microorganisms, its amplification and spread is through the improper utilization of antimicrobial agents, the use of fake and counterfeit medicines, poor prescribing habits and non-compliance to prescribed treatments (WHO) ². As a sustainable intervention, we offer our portfolio of top-quality anti-Infectives that improves patient outcomes and cost to treatment.

References

1. Jim O’Neill and Review Committee Members on Antimicrobial resistance: Tackling a crisis for the health and wealth of Nations (Review committee set up by the UK Government, December 2014)
2. WHO: Africa Health Monitor (Issue No. 16). Jean Bosco Ndihokubwayo et al. Antimicrobial resistance in the African Region: Issues, challenges and actions proposed.

Improving Access through Availability and Affordability: Up to 455,000 lives of children under five could be saved each year with improved access to antibiotics for treating pneumonia, a new study says (Centre for Disease Dynamics, Economics & Policy). The increase in antibiotic consumption notwithstanding, access to antibiotics is a continuing problem and more deaths are caused by the limited access and delays in access to antibiotics than by antibiotic resistance. Our intervention seeks to provide speedy and fast delivery of top quality antibiotics where they are needed and at an affordable price.

Right Treatment for Right Outcomes in all patient groups: In 2015, Africa was home to 88% of global malaria cases and 90% of malaria deaths (WHO), attesting to the disturbing fact that most malaria cases and deaths occur in sub-Saharan Africa¹. In areas with high transquest of malaria, children under 5 are particularly susceptible to infection, illness and death; more than two thirds (70%) of all malaria deaths occur in this age group. Early diagnosis and treatment of malaria reduces disease and prevents deaths. It also contributes to reducing malaria transquest. The best available treatment, particularly for P. falciparum malaria, is artemisinin-based combination therapy (ACT). Our portfolio of anti-malarial products is in line with WHO recommendation, manufactured under strict quality requirements and affordable to patients across countries in Africa.

References

1. WHO: Malaria Fact Sheet (January 2016)